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 We determined the natural history of immunoglobulin A 
nephropathy (IgAN) among patients who presented with mild 
proteinuria (0.2 to 0.4 g/day), and factors associated with 
development of adverse clinical events, defined as proteinuria
≧ 1.0g/day,　 blood　 pressure > 130/80mmHg,　 serum　 creatinine
≧ 1.4mg/dl.　 We　 did　 analyzed　 data　 from　 27　 patients(mean
age 30 ± 12 years) with IgAN accompanied by mild 
proteinuria between 1990 and 1998. We also evaluated 
semiquantitave scores of glomerulosclerosis, tubulointerstitial 
injury, hyaline arteriosclerosis, and IgAN classification. The 
median duration of follow-up was 51 months. During follow-
up, at least one adverse clinical event affected 15 patients 
(56%): among who eight (53%) developed proteinuria. And 
one of 8 developed impaired renal function and 7 (47%) be-
came hypertensive. Another 12 patients (44%) were not af-
fected by adverse clinical events. The clinical findings were 
not significantly different between the adverse events and 
no evens group. The scores of glomerulosclerosis and 
tubulointerstitial injury reveled significant differences be-
tween events. The only renal histological parameters of 
glomerulosclerosis and adverse clinical events were statisti-
cally correlated with renal survival. We concluded that IgAN 
with mild proteinuria frequently follows a slow by progres-
sive course and that the severity of glomerulosclerosis may 
be predictable prognostic factor in patients who have IgAN 
with by mild proteinuria. 
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Introduction
 Immunoglobulin A nephropathy (IgAN) is the most 
widespread primary glomerulonephritis worldwide and 
particularly in Japan [1,2]. This condition is one of the 
most important causes of end-stage renal disease 
(ESRD), which develops in up to 40% of patients who 
have had IgAN for 20 years [3-5]. Advanced age, hy-
pertension, proteinuria, and renal impairment at pres-
entation are poor prognostic indicators, but patients 
who present with isolated macroscopic or microscopic 
hematuria, are generally believed to have better a 
prognosis [5,6]. Most observations of the natural his-
tory of IgAN involve heterogeneous groups of patients 
with many different clinical permutations [8-10]. 
Recently, we reported that IgAN with proteinuria (0.5 
to 1.0 g/day) was slow progressive at the outpatient 
clinic [7]. Moreover, the severity of glomerulosclerosis 
may be the important prognostic factor in IgAN with 
proteinuria at the time of the initial biopsy [7]. The 
purpose of the present study is to determine the prog-
nosis of IgAN with mild proteinuria (0.2 to 0.4 g/day), 
we analyzed renal biopsied specimens and clinical 
data from the outpatient clinic.
Patients and Methods
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Patient Selection and Clinical Investigation
 We reviewed all patients who were diagnosed with 
IgAN from biopsy specimens at Nagasaki Municipal 
Medical Center (Nagasaki, Japan) during the period 
from 1990 to 1998. Primary IgAN were selected based 
upon four sets of criterias follows. 1) A diagnosis of 
IgAN based on predominant immune complexes con-
taining mesangial IgA detected by immunofluorecence 
in ultrastructures, irrespective of light microscopic
features; the intensity of immunofluorescence for IgA and 
C3 had to be at least 1+ on a scale of 3+. Patients with sys-
temic diseases such as diabetes, lupus erythematosus, 
chronic liver diseases, renal allografts, and Henoch-
Schonlein purpura were excluded. 2) A serum creatinine 
level below 1.3 mg/dl, an estimated 24-hour urinary 
creatinine clearance according to the Gault-Cockroft 
equation [8] of over 100 ml/min per 1.73 m2 of body 
surface area, proteinuria of 0.2 to 0.4 g per day, and 
no signs of hypertension at the time of renal biopsy. 
3) At least 6 glomeruli [9], 5 mm of cortex, and three 
arterioles were required in light microscopic sections. 
Records of 110 patients who fulfilled these criteria 
were reviewed and analyzed for age, sex, follow-up pe-
riod, serial serum creatinine levels, proteinuria, blood 
pressure, and renal outcome. 4) A minimum of 12 months 
of outpatient follow-up finally selected 27 patients.
Follow up for Adverse Clinical Events 
 We reviewed the clinical records of the remaining 
27 patients during treated with antiplatelet agents 
only. Adverse clinical events included proteinuria >_ 
1.0 g per day on two consecutive occasions; develop-
ment of hypertension, (systolic blood pressure > 130 
mmHg or diastolic blood pressure > 80 mmHg) and a 
need for antihypertensive therapy; impaired renal 
function when serum creatinine levels increased to 1.4 
mg/dl or greater, or an estimated 24-hour urinary 
creatinine clearance of < 70 ml/min per 1.73 m2 of 
body surface.
Renal Pathological Evaluation 
 Sections of biopsy specimens were stained with periodic 
acid-Schiff's reagent, periodic acid-Shiff-methenamine 
silver or Masson-trichrome. All renal biopsy specimens 
were reviewed by two investigators (Y.H., and T.T.) 
unaware of the patient's clinical condition in a double-
blind examination of the same slides. We graded renal 
biopsy specimens as described [10] and semiquantified 
the severity of glomerulosclerosis [ 11 ], tubulointerstitial 
damage, and hyaline arteriosclerosis [12]. The ratio (%) 
of glomerulosclerosis was determined after excluding 
glomeruli located within areas of subcapsular scar. 
The summarized grading scores were as follows. 
 Classification of IgAN. Grade 1, minor change; Grade 
2, segmental mild proliferation; Grade 3, segmental 
moderate or global mild proliferation; Grade 4, global 
moderate proliferation and Grade 5, global severe pro-
liferation. The grade was calculated as the mean value 
for the degree of mesangial proliferation for all 
glomeruli evaluated (Figure 1). Glomerulosclerotic 
scores (GS): 0, no sclerosis; 1, sclerosis of 25% or less; 
2, sclerosis of 26% to 50%; 3, sclerosis of 51% to 75%; 4,
Figure 1. Classification of immunoglobulin A nephropathy. 
a: Grade 1, minor change; b: Grade 2, segmental mild prolifera-
tion; c: Grade 3, segmental moderate or global mild prolifera-
tion; d: Grade 4, global moderate proliferation; e: Grade 5, 
global severe proliferation. Periodic acid-Schiff; original magni-
fication x 150.
sclerosis of 76% to 100%. 
 Tubulointerstitial score (TIS). The areas of tubular at-
rophy and interstitial fibrosis in the renal cortex, re-
gardless of inflammatory cells, were estimated in ratios 
(%) and graded as follows: Grade 0, tubular atrophy and 
interstitial fibrosis were absent or less than 5%; Grade 1, 
5% to 49%; and Grade 2, 50% or greater (Figure 2).
Figure 2. Tubulointerstitial score. The areas of tubular atro-
phy and interstitial fibrosis in the renal cortex, regardless of 
inflammatory cells, were estimated in ratios (%). a: Grade 0, 
tubular atrophy and interstitial fibrosis were absent or less 
than 5%; b: Grade 1, 5% to 49%; c: Grade 2, 50% or greater. 
Masson-trichrome; original magnification x 120.
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Table 1. Clinical characteristics at the time of presentation in 
events and no events groups
Figure 3. Hyaline arteriosclerosis. 
a: Grade 1, present; b: Grade 0, absent. Periodic acid-Schiff; 
original magnification x 200.
 Hyaline arteriosclerosis (HA) was recorded as Grade 
1, present or Grade 0, absent (Figure 3).
Statistical Analysis
 All statistical analyses were performed using 
Statview 5.0 for Windows software (SAS Institute Inc., 
Cary, USA). Results are expressed as means ± SD un-
less otherwise stated. Statistical significance was ex-
amined using the Mann-Whitney U test with the 
Bonferroni correction. The incidence of adverse events 
was estimated using the Kaplan-Meier method and 
compared using the log rank test. Multivariate analy-
sis was not performed because of the relatively small 
number of selected patients. Variables included age at 
presentation, sex, serum IgA level, presence of macro-
scopic hematuria, presence of detectable proteinuria 
(0.2 to 0.4 g/day) at presentation, and the histologic 
grade of the renal biopsy specimen. A P value below 
0.05 was considered statistically significant.
Results
                              Events group No events group 
P                           (
n = 15) (n = 12) value 
Age (years) 38--12 24±5 0.06 
Gender (M/F) 9/6 5/7 0.34 
Duration time (month) 44±32 59±32 0.07 
Body mass index (kg/mm2) 23.3±2.8 22.8±3.3 0.90 
Serum creatinine (mg/dl) 0.9±0.2 0.8±0.2 0.31 
Urine creatinine (mg/dl) 110±67 93--40 037 
Creatinine clearance (ml/min) 115 ± 15 122±20 0.30 
Serim Immunoglobulon A (mg/dl) 359±114 344--129 0.40 
Fibrinogen 263±48 249±77 0.83 
Serum complement titer (U/ml) 36.8±2.9 36.2±4.3 0.78 
Uric acid (mg/dl) 5.9± 1.2 5.4± 1.1 0.60 
Macrohematuria 1/15 4/12 0.08
Value expressed as mean -LSD. n: number of patients
 The mean age of the 14 male and 13 female pa-
tients at presentation was 30 ± 12 years (range 16 to 
62). At presentation, 7 patients (26%) had elevated 
serum IgA concentrations (110 to 410 mg/dl) and none 
of the 27 had low serum complement levels. The me-
dian follow-up was 51 months (range 12 to 137), dur-
ing which, 15 patients (56%) developed at least one ad-
verse event (events group). 8 of these patients (53%) 
developed proteinuria and 3 of those 8 had hyperten-
sion. And that one developed impaired renal function 
that progressed to ESRD 60 months after initial pres-
entation and 7 (47%) became hypertensive. Another 12 
patients (44%) had persistent abnormalities in urinaly-
sis examinations, without development of adverse events 
(no events group). Adverse events developed within a 
median of 41 months (range 6 to 126). The clinical 
findings were not significantly different between the 
two groups (Table 1). We summarized pathological
Table 2. Comparison of renal histopathologic findings in 
immunogloburin A nephropathy in patients with events and 
those with no events groups
                           Events group No events group 
                          (n = 15) (n = 12) P value 
Classification of IgAN 3.16±0.98 2.83± 1.14 0.62 
Glomeruloscl erotic score (GS) 0.83±0.79 0.17±0.37 0.02 
Tubulointerstitial score (TIS) 2.25±0.72 1.33±0.62 0.01 
Hyaline arteriosclerosis (HA) 0.17±0.37 0.75±0.37 0.14 
Value expressed as mean ±SD. n: number of patients
changes in renal biopsy specimens from the 27 pa-
tients (Table 2). The Glomerulosclerotic score (GS) and 
Tub ulointerstitial score (TIS) showed significant differ-
ences between the groups (P = 0.02 and P = 0.01, re-
spectively), but the hyaline arteriosclerosis (HA), classi-
fications of IgAN were not significantly different. 
However, although renal survival rates until develop-
ment of adverse clinical events did not significantly 
differ from TIS, HA and Classification of IgAN (Figure 
5-7), it was significantly higher when GS were low (P 
< 0.01) (Figure 4).
Figure 4. Renal survival rates in with mild proteinuria 
(0.2 to 0.4 g per day) assessed by glomerulosclerotic 
score. Survival rates were significantly higher when 
glomerulosclerotic scores were low (P < 0.01).
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Figure 5. Renal survival rates in immunoglobulin 
A nephropathy with mild proteinuria assessed by 
tubulointerstitial score. Survival rates did not sig-
nificantly differ (P = 0.47).
Figure 6. Renal survival rates in immunoglobulin 
A nephropathy with mild proteinuria with hyaline 
arteriosclerosis. Survival rates were not signifi-
cantly affected (P = 0.54).
Figure 7. Renal survival rates in immunoglobulin 
A nephropathy with mild proteinuria according to 
classification. Survival rates did not significantly 
differ (P = 0.87).
Discussion
 In this study, we examined the natural history of IgAN 
among patients who presented with mild proteinuria (0.2 
to 0.4 g/day) during treated with antiplatelet agents only. 
Among these, over 56% of them developed proteinuria, 
hypertension, or impaired renal function during the 
follow up median of 51 months. The severity of 
glomerulosclerosis and tubulointerstitial injury signifi-
cantly correlated with adverse clinical events including
subsequent proteinuria, hypertension, and impaired 
renal function. The only renal histological parameters 
of glomerulosclerosis and adverse clinical events were 
statistically correlated with renal survival. Clarkson et 
al. [13] reported that a tendency to progression was 
suggested by the presence of glomerulosclerosis. 
Moreover, To et al. [14] suggested that although the 
severity of glomerulosclerosis was the only morphological 
parameter that independently correlated with renal sur-
vival in adult patients with IgAN when the renal patho-
logical characteristics of individual patients are assessed 
in clinical practice, information about tubulointerstitial 
injury and hyaline arteriosclerosis may be useful. 
Therefore, we postulate that glomerulosclerosis may de-
termine the prognosis of IgAN with mild proteinuria. 
 Although many grading systems have correlated 
histological lesions with the clinical outcome of IgAN, 
none of them have prevailed because of several limita-
tions, and independent prognostic significance has not 
been shown for any of them [15-20]. One of the major 
limitations is the complexity of a grading system re-
lated to the inclusion of both acute and chronic le-
sions. Thus, the potential importance of chronicity in-
dices may be masked. The importance of chronic lesions 
and of assessing glomerular and tubulointerstitial damage 
in the appraisal of IgAN has been reported [10,18-21]. 
We therefore exclusively focused on chronic irreversible 
lesions and used a chronicity-based histological grad-
ing system that assessed GS, TIS, and HA over a long-
term follow-up. We believe that this scoring system is 
convenient, simple to understand as a prognosticator in 
IgAN and inter and intra observer findings closely 
match. Our methods to determine prognostic factor in 
IgAN will need evaluating in a larger patients with 
IgAN. 
 Only one patient in the study group developed im-
paired renal function, and this progressed to ESRD 60 
months after initial presentation. Impaired renal func-
tion in patients with IgAN is always preceded by the 
development of proteinuria followed by hypertension 
[22]. The practical implication is that regular monitor-
ing of blood pressure and proteinuria are the two most 
important steps to identify patients at risk of deterio-
ration [22]. We found that mild proteinuria at presen-
tation was an indicator of adverse events: 8 (53%) de-
veloped proteinuria and 7 (47%) became hypertensive 
during follow up. These results suggest that mild 
proteinuria is one marker of IgAN progression. 
 We concluded that IgAN with mild proteinuria fre-
quently follows a slowly progressive course and that 
the severity of glomerulosclerosis may be predictable 
prognostic factor for IgAN with by mild proteinuria 
at the time of the initial biopsy.
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